Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyDavid M. Ross, Timothy P. Hughes, David T Yeung et al.|Blood|2013Cited by 705
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsDavid T Yeung, Timothy P. Hughes, Michael Osborn et al.|Blood|2014Cited by 102
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cellsTimothy P. Hughes, David M. Ross, Ilaria S. Pagani et al.|Leukemia|2018Cited by 78